Back to results
US 2006/0223753 A1Published application
IGF-I and IGF-2 chimeric polypeptides and therapeutic uses thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorDavid Glass
Life of this patent
Estimating the term…
Abstract
A chimeric protein comprising an IGF1 and an IGF2 component and optionally a fusion component (F) and/or a signal sequence, exhibiting improved activity relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound.
Claims20
A chimeric IGF polypeptide, comprising:
- (a) an IGF2 derived component comprising about amino acid 7 through about amino acid 37 of IGF2 (SEQ ID NO:3) and an IGF1 derived component comprising about amino acid 38 to about amino acid 64 of IGF1 (SEQ ID NO:1), or (b) an IGF1 derived component comprising amino acid 4 to amino acid 36 of SEQ ID NO:1 and an IGF2 derived component comprising about amino acid 39 to about amino acid 64 of IGF2, and optionally (c) a fusion component (F) and/or (d) a signal sequence.
A chimeric IGF polypeptide comprising a polypeptide having a sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:11.
Dependencies are inferred from the claim text.